Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial.
exercise tolerance
fatigue
gait
multiple sclerosis
remote ischemic preconditioning
Journal
BMJ neurology open
ISSN: 2632-6140
Titre abrégé: BMJ Neurol Open
Pays: England
ID NLM: 101775450
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2019
revised:
22
01
2020
accepted:
04
02
2020
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals. This study aimed to assess the effect of RIPC on walking in people with multiple sclerosis (MS). This was a double-blind randomised controlled clinical trial. We used three cycles of RIPC delivered by occluding the upper arm with a blood pressure (BP) cuff inflated to a pressure of 30 mm Hg above the systolic BP. In patients in the sham intervention group, the BP cuff was inflated only to 30 mm Hg below diastolic BP. Outcome measures included the Six-Minute Walk Test (6MWT), gait speed, the Borg rate of perceived exertion (RPE) scale, the tolerability of the RIPC using a Numerical Rating Scale for discomfort from 0 to 10, and adverse events. We identified responders meeting the minimal clinically important difference (MCID) established in the literature in each group. Seventy-five participants completed the study (RIPC: 38 and Sham: 37). The distance walked during the 6MWT improved by 1.9% in the sham group and 5.7% in the RIPC group (p=0.012). The number of responders meeting MCID criteria in the RIPC group was significantly greater compared with the sham intervention group. No serious adverse events occurred. Single cycle of RIPC resulted in immediate improvement in walking distances during 6MWT in people with MS. NCT03153553.
Sections du résumé
BACKGROUND
BACKGROUND
Remote ischaemic preconditioning (RIPC) is the exposure of body parts to brief periods of circulatory occlusion and reperfusion. Recent studies have also shown that RIPC can improve exercise performance in healthy individuals.
OBJECTIVE
OBJECTIVE
This study aimed to assess the effect of RIPC on walking in people with multiple sclerosis (MS).
METHODS
METHODS
This was a double-blind randomised controlled clinical trial. We used three cycles of RIPC delivered by occluding the upper arm with a blood pressure (BP) cuff inflated to a pressure of 30 mm Hg above the systolic BP. In patients in the sham intervention group, the BP cuff was inflated only to 30 mm Hg below diastolic BP. Outcome measures included the Six-Minute Walk Test (6MWT), gait speed, the Borg rate of perceived exertion (RPE) scale, the tolerability of the RIPC using a Numerical Rating Scale for discomfort from 0 to 10, and adverse events. We identified responders meeting the minimal clinically important difference (MCID) established in the literature in each group.
RESULTS
RESULTS
Seventy-five participants completed the study (RIPC: 38 and Sham: 37). The distance walked during the 6MWT improved by 1.9% in the sham group and 5.7% in the RIPC group (p=0.012). The number of responders meeting MCID criteria in the RIPC group was significantly greater compared with the sham intervention group. No serious adverse events occurred.
CONCLUSION
CONCLUSIONS
Single cycle of RIPC resulted in immediate improvement in walking distances during 6MWT in people with MS.
TRIAL REGISTRATION NUMBERS
BACKGROUND
NCT03153553.
Identifiants
pubmed: 33681776
doi: 10.1136/bmjno-2019-000022
pii: bmjno-2019-000022
pmc: PMC7903187
doi:
Banques de données
ClinicalTrials.gov
['NCT03153553']
Types de publication
Journal Article
Langues
eng
Pagination
e000022Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Strength Cond Res. 2015 Jan;29(1):80-5
pubmed: 25068802
Front Neurol. 2018 Jun 19;9:475
pubmed: 29971043
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Sports Med. 2016 Oct;46(10):1575-6
pubmed: 27459863
Patient. 2011;4(3):189-201
pubmed: 21766914
Trials. 2015 Oct 15;16:468
pubmed: 26470880
Med Sci Sports Exerc. 2012 Nov;44(11):2084-9
pubmed: 22843115
Nat Rev Neurol. 2015 Dec;11(12):698-710
pubmed: 26585977
Arch Phys Med Rehabil. 2017 Jul;98(7):1435-1452
pubmed: 28088382
Arch Phys Med Rehabil. 2016 Jun;97(6):974-82
pubmed: 26836954
Mult Scler. 2013 Nov;19(13):1784-91
pubmed: 23587605
J Card Surg. 2010 Jan-Feb;25(1):127-34
pubmed: 19549044
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1435-43
pubmed: 12791590
N Engl J Med. 2015 Oct 8;373(15):1397-407
pubmed: 26436208
Sports Med. 2016 Apr;46(4):531-44
pubmed: 26645697
Neurorehabil Neural Repair. 2014 Sep;28(7):621-31
pubmed: 24503204
Arch Phys Med Rehabil. 2010 Sep;91(9):1410-7
pubmed: 20801260
Orphanet J Rare Dis. 2017 Apr 26;12(1):78
pubmed: 28441951
Arch Phys Med Rehabil. 2016 Apr;97(4):633-645.e29
pubmed: 26751247
Arch Phys Med Rehabil. 2016 Sep;97(9 Suppl):S210-7
pubmed: 27211007
Acta Cir Bras. 2013 Jun;28(6):441-6
pubmed: 23743682
Eur J Appl Physiol. 2010 Jan;108(1):141-6
pubmed: 19760432
Disabil Rehabil. 2005 Nov 30;27(22):1365-71
pubmed: 16372431
Ann Clin Transl Neurol. 2019 Jan 16;6(2):364-372
pubmed: 30847368
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1403-10
pubmed: 17446439
Physiol Rep. 2014 Nov 20;2(11):
pubmed: 25413320